Abstract

Objective To study the effect of recombinant human endostatin (Endostar) combined with VP regimen (cisplatin and vindesine) on levels of tumor markers in peripheral blood of patients with advanced non small cell lung cancer (NSCLC). Methods Eight-four patients with advanced NSCLC admitted to our hospital were divided into control group and treatment group (with 42 cases in each group) according to different treatment plans. The patients in the control group were treated with VP regimen, while the patients in treatment group were treated with recombinant human endostatin combined with VP regimen. The curative effect, vascular endothelial growth factor (VEGF), serum tumor markers and adverse reactions were compared between the two groups. Results The disease control rate in the treatment group was 73.81%, while that in the control group was 42.86% (P 0.05). Conclusions Recombinant human endostatin combined with VP regimen can improve the short-term therapeutic effect on patients with advanced NSCLC, and reduce the levels of serum VEGF and tumor markers, with few side effects, is safe and effective. Key words: Recombinant human endostatin; VP regimen; Advanced non small cell lung cancer; Tumor marker

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.